Search clinical trials for: HER3 mutation

Total 3312 results

Amsterdam UMC, location VUmc
ADHDcentraal

Completed

The Day-time Response Variation of (Lis)Dexamphetamine (IDEAL)

Adhd

Netherlands
Hummingbird Bioscience

Recruiting

Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation

Pancreatic Cancer | Non-Small Cell Lung Cancer | Metastatic Solid Tumor | Locally Advanced Solid Tumor

Australia
Daiichi Sankyo

Recruiting

HER3-DXd in Metastatic or Unresectable Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer (NSCLC)

United States, Korea, Republic of, Spain, Japan, Netherlands, Taiwan
Cancer Research UK
Hummingbird Bioscience

Recruiting

HMBD-001 in Advanced HER3 Positive Solid Tumours

Melanoma | Cervical Cancer | Gastric Cancer | Pancreatic Cancer | Ovarian Cancer | Hepatocellular Carcinoma (HCC) | Bladder Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Castration-resistant Prostate Cancer | Non-small Cell Lung Cancer (NSCLC) | Oesophageal Cancer | RAS Wild Type Colorectal Cancer | Squamous Cell Cancer of the Head and Neck

United Kingdom
GlaxoSmithKline

Completed

Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors

Neoplasms | Cancer

Australia, United States, Netherlands
The Netherlands Cancer Institute
Daiichi Sankyo, Inc.

Not yet recruiting

Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT

EGFR Gene Mutation | Non-Small Cell Lung Carcinoma | Advanced Non-Small Cell Squamous Lung Cancer
Daiichi Sankyo, Inc.

Completed

Study to Assess Pharmacokinetics, Immunogenicity and Safety/Tolerability of Patritumab (U3-1287)

Solid Tumors

United States
Sihuan Pharmaceutical Holdings Group Ltd.
Covance; XuanZhu Pharma Co., Ltd.

Completed

A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States
Shanghai Institute Of Biological Products
Shanghai Pulmonary Hospital, Shanghai, China

Not yet recruiting

A Clinical Trial of SIBP-A13 Injection in the Treatment of Advanced Malignant Solid Tumor Patients.

Advanced Solid Tumor
Daiichi Sankyo
Merck Sharp & Dohme LLC; AstraZeneca

Recruiting

HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer (NSCLC)

United States, Korea, Republic of, Taiwan, Japan
Daiichi Sankyo Co., Ltd.
Daiichi Sankyo, Inc.

Completed

Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer

Metastatic Breast Cancer

United States, Japan
SOLTI Breast Cancer Research Group
Daiichi Sankyo, Inc.

Active, not recruiting

A Window-of-opportunity Study of U3-1402, a HER3-targeting Antibody-drug Conjugate in Operable Breast Cancer According to ERBB3 Expression (TOT-HER3)

Breast Cancer

Spain
GlaxoSmithKline

Completed

Immuno Positron Emission Tomography Study of GSK2849330 in Subjects With Human Epidermal Growth Factor Receptor 3-Positive Solid Tumors

Neoplasms | Cancer

Netherlands
AVEO Pharmaceuticals, Inc.

Completed

A Phase 1 Dose Escalation Study of AV-203, an ERBB3 Inhibitory Antibody, in Subjects With Advanced Solid Tumors

Solid Tumors

United States
Taiho Oncology, Inc.

Terminated

A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities

Advanced Solid Tumors With HER2 Abnormalities | Advanced Solid Tumors With HER3 Abnormalities

United States, Spain, France, United Kingdom
AZ-VUB

Unknown

An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation

Cancers Harbouring an EGFR Mutation, (Excluding Non-squamous Non- Small Cell Lung Cancer, a Registered Indication), a HER2 Mutation or a HER3 Mutation

Belgium
Salubris Biotherapeutics Inc

Recruiting

Study of JK07 in Patients With Chronic Heart Failure (RENEU-HF)

Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction

United States
Hummingbird Bioscience
Merck KGaA, Darmstadt, Germany

Recruiting

Study of an Anti-HER3 Antibody, HMBD-001, With Docetaxel +/- Cetuximab in Advanced Squamous Non-small Cell Lung Cancers

Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

Australia, Singapore
DualityBio Inc.

Recruiting

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

Advanced Solid Tumor

United States, China
Herbert Lyerly

Recruiting

Assessing the Immunogenicity of pING-hHER3FL

Advanced Cancer

United States
Shanghai Institute Of Biological Products
Fudan University

Completed

A Phase Ⅰa Clinical Study Exploring Efficacy of SIBP-03 When Treating the Patients With Advanced Malignant Solid Tumors.

Tumor

China
Salubris Biotherapeutics Inc

Completed

Study of JK07 in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF)

Heart Failure With Reduced Ejection Fraction

United States
U3 Pharma GmbH

Completed

Phase I Study of U3P1287/01, Including Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States
H. Lee Moffitt Cancer Center and Research Institute
The Shulas' Foundation

Recruiting

DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer (DecipHER)

Triple Negative Breast Cancer | HER2-negative Breast Cancer

United States
Daiichi Sankyo

Available

Medical Access Program for Patritumab Deruxtecan

Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer

United States
Gustave Roussy, Cancer Campus, Grand Paris
Daiichi Sankyo, Inc.

Recruiting

Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer (ICARUS-BREAST)

Metastatic Breast Cancer

France
King's College London
Guy's and St Thomas' NHS Foundation Trust; Brighton and Sussex University Hospitals...

Recruiting

A Study to Measure the Expression of the HER2-HER3 Dimer in Tumour and Blood (Exosomes) Samples From Patients With HER2 Positive Breast Cancer Receiving HER2 Targeted Therapies (HERdi PREDICT)

HER2-positive Breast Cancer

United Kingdom
MedSIR
Daiichi Sankyo

Recruiting

HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease (TUXEDO-3)

Metastatic Breast Cancer | Solid Tumor, Adult | Advanced Non-Small Cell Squamous Lung Cancer

Spain, Austria
Daiichi Sankyo
Merck Sharp & Dohme LLC

Recruiting

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Melanoma | Cervical Cancer | Head and Neck Cancer | Gastric Cancer | Esophageal Cancer | Prostate Cancer | Bladder Cancer | Advanced Solid Tumor | Endometrial Cancer | Ovarian Carcinoma | Pancreatic Carcinoma

United States, Taiwan, Japan
Daiichi Sankyo

Active, not recruiting

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

EGFR L858R | EGFR Exon 19 Deletion | Nonsquamous Non-small Cell Lung Cancer

Korea, Republic of, United States, Netherlands, Spain, United Kingdom, Japan, Austria, Belgium, Italy, France, Taiwan, Germany, Australia, Singapore, China, Hong Kong, Norway, Canada, Poland, Portugal, Switzerland
Daiichi Sankyo, Inc.
Parexel

Terminated

Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung) (HER3-Lung)

Lung Cancer | Non-small Cell Lung Cancer

United States, Italy, Poland, United Kingdom, Belgium, Spain, Canada, Germany, Czechia, Hungary
Daiichi Sankyo, Inc.

Completed

A Study of Prevalence of HER3 Expression in Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

United States
Daiichi Sankyo
Daiichi Sankyo Co., Ltd.

Active, not recruiting

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer Metastatic | Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

United States, Spain, Korea, Republic of, France, United Kingdom, Taiwan, Australia, Japan, China, Netherlands, Italy, Germany, Austria, Belgium, Bulgaria, Singapore
Merrimack Pharmaceuticals

Completed

A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers (Monotherapy)

Metastatic Breast Cancer | Her2 Amplified Solid Tumors

United States
Shanghai Institute Of Biological Products

Not yet recruiting

Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma
Gustave Roussy, Cancer Campus, Grand Paris
Daiichi Sankyo

Recruiting

Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd (ICARUSBREAST02)

Advanced Breast Cancer | HER2-positive Metastatic Breast Cancer | Breast Cancer Metastatic | HER2 Low Breast Carcinoma

France
Sichuan Baili Pharmaceutical Co., Ltd.
SystImmune Inc.

Recruiting

A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial Tumors

Locally Advanced or Metastatic Epithelial Tumor

China
Cancer Insight, LLC
Genentech, Inc.; Sellas Life Sciences Group

Completed

Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients (HER3+)

Breast Cancer

United States
Merrimack Pharmaceuticals
Sanofi

Completed

Phase I Safety Study of the Drug MM-121 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment

Advanced Solid Tumors

United States
Merrimack Pharmaceuticals

Completed

MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer

Breast Neoplasms

United States
Merus N.V.

Available

Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor

Renal Cell Carcinoma | Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Prostate Cancer | Non Small Cell Lung Cancer | Cholangiocarcinoma | Solid Tumor, Unspecified, Adult | Unknown Primary Tumors | NRG1 Fusion
Hoffmann-La Roche

Completed

Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE)

Ovarian Cancer

Italy, Austria, Belgium, France, Germany, Spain, Netherlands, Sweden, Denmark, Norway
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | KRAS Gene Mutation | Metastatic Malignant Solid Neoplasm | EGFR Gene Mutation | ERBB2 Gene Amplification | ERBB2 Gene Mutation | EGFR Gene Amplification | ERBB3 Gene Mutation | ERBB4 Gene Mutation

United States
Roswell Park Cancer Institute
United States Department of Defense

Recruiting

Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma | Metastatic Malignant Neoplasm in the Brain

United States
SCRI Development Innovations, LLC
Daiichi Sankyo, Inc.

Recruiting

A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer

Metastatic Breast Cancer | Locally Advanced Breast Cancer

United States
Yonsei University

Withdrawn

Efficacy of Triplet Combination With Pembrolizumab, Neratinib, and Paclitaxel as a Second Line Treatment in Recurrent/Advanced Gastric Cancer Having Somatic Human Epidermal Growth Factor Receptor Family (EGFR, HER2, HER3, HER4) Mutations or HER2 Amplification/Overexpression

Recurrent/Advanced Gastric Cancer

Korea, Republic of
Merus N.V.

Recruiting

A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

NSCLC Harboring NRG1 Fusion | Solid Tumours Harboring NRG1 Fusion | Pancreatic Cancer Harboring NRG1 Fusion | NRG1 Fusion

Spain, France, Israel, Belgium, Denmark, United States, Korea, Republic of, Japan, Germany, Netherlands, Austria, Canada, Italy, Norway, Singapore, Sweden, Taiwan, United Kingdom
Hoffmann-La Roche

Completed

A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin

Neoplasms

Spain, Korea, Republic of, Netherlands, Denmark
Merus N.V.

Completed

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

Breast Cancer Metastatic

United States, France, Belgium, Spain, United Kingdom, Netherlands, Portugal
Merrimack Pharmaceuticals

Completed

A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Spain, Taiwan, United States, Canada, Korea, Republic of, Germany

Search clinical trials for: HER3 mutation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Paraguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations